Moreover, these results pointed out that targeting downstream components in the kallikrein cascade, such as the bradykinin receptors B1R and B2R, could also be useful, as it has been demonstrated for other pathologies such as airway inflammation, diabetic neuropathy, brain ischemia, arthritis and neuropathic pain [12]. This evidence concerns the gene BDKRB1 and arthritic joint disease.